Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 RON | 0.00% | +0.57% | +19.86% |
1st Jan change | Capi. | |
---|---|---|
+19.86% | 535M | |
+25.24% | 45.32B | |
+34.85% | 24.51B | |
+29.56% | 16.85B | |
+21.32% | 14.62B | |
+70.51% | 14.16B | |
-0.05% | 6.79B | |
+15.74% | 5.82B | |
-8.87% | 5.73B | |
+10.29% | 4.93B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology